Targeted Oncology Staff

Joshi Alumkal, MD assessed the available checkpoint inhibitors for the treatment of mutated metastatic castration-resistant prostate cancer.

During a virtual Targeted Oncology Case-Based Roundtable event, Marcia S. Brose, MD, PhD, led a peer discussion about frontline treatment of a patient with differentiated thyroid cancer.

Neratinib demonstrated single-agent efficacy with significant response and survival rates in tyrosine kinase inhibitor-refractory patients with non– small cell lung cancer whose tumors harbor EGFR exon 18 mutations.

Assessing prognosis is an important step prior to treatment selection for a patient with classic Hodgkin lymphoma, explained Joseph Michael Tuscano, MD. Other steps aid in the treatment and management of toxicity.

Alicia K. Morgans, MD, MPH, associate professor of Medicine, Feinberg School of Medicine, Northwestern University, reviewed the clinical trial results for multiple hormonal therapies intended to treat prostate cancer. She explained that many of them show similar outcomes.

Thomas G. Martin, MD discussed the case of a patient with newly-diagnosed multiple myeloma during a virtual Targeted Oncology Case-Based Roundtable event.

A number of clinical trials have provided evidence of efficacy of combination regimens for the treatment of RET-mutant medullary thyroid cancer. During a virtual Targeted Oncology Case-based Roundtable event, Lori Wirth, MD, discussed the options for a 58-year-old man with RET-mutant medullary thyroid cancer.

During a virtually held Targeted Oncology Case-Based Roundable event, Meghan Mooradian, MD, discussed the case of a 63-year-old patient diagnosed with non–small cell lung cancer.

Hedgehog inhibitors are becoming more widely used for Basal cell carcinoma. Two experts, Shailender Bhatia, MD and Paul T. Nghiem, MD, PhD discussed the reality of hedgehog inhibitor use in practice during a virtual Targeted Oncology Case-Based Roundtable event.

During a virtual Targeted Oncology Case-Based Roundtable event, Eleni Efstathiou, MD, PhD, discussed the case of a 75-year-old patients with metastatic castration-resistant prostate cancer.

Jessica Donnington, MD, led a discussion with a group of peers regarding treatment of non–small cell lung cancer during a virtual Targeted Oncology Case-Based Roundtable event.

During a virtual Targeted Oncology Case-Based Roundtable event, Daniel O. Persky, MD, reviewed the case of a 61-year-old patient with chronic lymphocytic leukemia.

During a virtual Targeted Oncology Case-Based Roundtable, Ajai Chari, MD. a professor of Medicine, Hematology, and Medical Oncology at the Icahn School of Medicine at Mount Sinai in New York, NY, discussed the case of a 72-year-old patient with multiple myeloma.

During a virtual Targeted Oncology Case-Based Roundtable event, Anish B. Parikh, MD, discussed front-line treatment options for metastatic urothelial cancer as well as the data supporting avelumab maintenance.

Corey J. Langer, MD, discusses treatment options for a patient with non–small cell lung cancer based on the clinical trial research.

During a Targeted Oncology virtual Case-Based Roundtable event, William K. Oh, MD, reviewed the data from the CARD trial as he shared the case of a 75-year-old man with metastatic castration-resistant prostate cancer (mCRPC) with a group of peers.

Pierluigi Porcu, MD, explained how the combination of brentuximab vedotin plus chemotherapy works in in frontline setting of Hodgkin lymphoma during a virtual Targeted Oncology Case-Based Roundtable event.

David Dingli, MD, PhD, professor of Medicine at the Mayo Clinic, reviews the combination therapies available for the treatment of multiple myeloma in a patient who is 72-years-old and transplant-ineligible.

Tulio E. Rodriguez, MD, weighs the various treatment options available for a patient with multiple myeloma.

During a Targeted Oncology Case-Based Peer Perspective event, Kathleen Moore, MD, discussed the combination of bevacizumab and olaparib as treatment of ovarian cancer.

During a Targeted Oncology Case-Based Peer Perspectives event, Ulka Nitin Vaishampayan, MBBS, FAB, discussed the case of a 72-year-old patients with metastatic castration-resistant prostate cancer.

For the treatment of patients with lung cancer and low PD-L1 expression, immunotherapy-based combinations have been shown effective through clinical trial research. Stephen Liu, MD, reviewed the studies during a Targeted Oncology Case-Based Peer Perspectives virtual event.

The FDA has approved trilaciclib (Cosela) as a first-in-class agent to help reduce the frequency of chemotherapy-induced bone marrow suppression in adults receiving chemotherapy for extensive-stage small cell lung cancer.

The FDA has granted approval to lisocabtagene maraleucel a CD19-targeting chimeric antigen receptor T-cell therapy, for the treatment of adult patients with relapsed or refractory large B-cell lymphoma who have received at least 2 prior lines of systemic therapy.

During a Targeted Oncology Case-Based Peer Perspectives event, Sara M. Tolaney, MD, MPH, discussed therapies available for the treatment of a 42-year-old woman with HER2-positive breast cancer.

Raajit K. Rampal, MD, PhD, hematologic oncologist, Memorial Sloan Kettering Cancer Center, reviewed the prognostic tools used to find indicators of response to treatment in patients with myelofibrosis, during a Targeted Oncology Case-Based Peer Perspective Roundtable discussion.

During a Targeted Oncology Case-Based Peer Perspectives event, Guilherme Rabinowits, MD, medical oncologist/hematologist, Miami Cancer Institute, discussed the case of 69-year-old patients with cutaneous squamous cell carcinoma.

The combination of atezolizuma plus carboplatin and etoposide demonstrated improvement in overall survival and progression-free survival when given as maintenance therapy to patients extensive stage small cell lung cancer, according to the latest findings from the IMpower 133 trial.

During a Targeted Oncology Case-Based Peer Perspectives Roundtable, Swaminathan P. Iyer, MD, discussed FDA-approved therapy option for a patient with T-cell lymphoma.

The role of Bruton's tyrosine kinase inhibitors in chronic lymphocytic leukemia is supported by clinical trial research. During a Targeted Oncology Case-Based Peer Perspectives Roundtable event, Peter Hillmen, MB ChB, PhD, provided evidence around acalabrutinib for the case of a 61-year-old woman.